Chemoresistance in high-grade gliomas: Relevance of adenosine signalling in stem-like cells of glioblastoma multiforme

Current Drug Targets

Volumn 15, Issue 10, 2014, Pages 931-942

  Garrido, Wallys ^a   Rocha, José Dellis ^a   Jaramillo, Catherinne ^a   Fernández, Katia ^b   Oyarzún, Carlos ^a   Martín, Rody San ^a   Quezada, Claudia ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

Author keywords

Adenosine; Adenosine A3 receptor; Glioblastoma multiforme; Glioblastoma stem like cells; Multiple drugs resistance associated protein 1 (Mrp1) transporter

Indexed keywords

5' NUCLEOTIDASE; ABC TRANSPORTER; ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE PHOSPHATE; BEVACIZUMAB; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUNG RESISTANCE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; RAL PROTEIN; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOSENSITIZATION; DRUG TARGETING; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOBLASTOMA STEM LIKE CELL; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOTHERAPY; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECURRENT DISEASE; SURVIVAL RATE; BRAIN NEOPLASMS; CANCER STEM CELL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ADENOSINE; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84925946155     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: None     Document Type: Article

References (174)

1. Quezada C, Peigñan L, Segura R, et al. Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme. Rev Med Chil 2011; 39(4): 415-24.
2. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010; 17(4): 417-21.
3. Peigñan L, Garrido W, Segura R, et al. Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro. Neurochem Res 2011; 36(8): 1397-406.
4. Quant EC, Wen PY. Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. Neuroimaging Clin N Am 2010; 20(3): 425-48.
5. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010; 67(3): 279-83.
6. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63(18): 5821-8.
7. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006; 6(6): 425-36.
8. Natsume A, Kinjo S, Yuki K, et al. Glioma-initiating cells and molecular pathology: implications for therapy. Brain Tumor Pathol 2011; 28(1): 1-12.
9. Tabatabai G, Weller M. Glioblastoma stem cells. Cell Tissue Res 2011; 343(3): 459-65.
10. Lobo NA, Shimono Y, Qian D, et al. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-99.
11. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011; 89(4): 491-502.
12. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444(7120): 756-60.
13. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
14. Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007; 1(4): 353-55.
15. Bleau AM, Holland EC. Chemotherapeutic treatment of gliomas increases the amount of cancer stem-like cells. Med Sci (Paris) 2009; 25(10): 775-7.
16. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13(7): 1238-41.
17. Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006; 54(8): 850-60.
18. Altaner C. Glioblastoma and stem cells. Neoplasma 2008; 55(5): 369-74.
19. Jin F, Zhao L, Guo YJ, et al. Influence of Etoposide on antiapoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. Brain Res 2010; 1336: 103-11.
20. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008; 68(15): 6043-8.
21. Huang Z, Cheng L, Guryanova OA, et al. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell 2010; 1(7): 638-55.
22. Gatti L, Beretta GL, Cossa G, et al. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem 2009; 9(9): 1102-12.
23. Garrido W, Munoz M, San Martin R, et al. FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistanceassociated protein-1. Biochem Biophys Res Commun 2011; 411(1): 62-8.
24. Bi CL, Fang JS, Chen FH, et al. Chemoresistance of CD133(+) tumor stem cells from human brain glioma. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007; 32(4): 568-73.
25. Jin F, Zhao L, Zhao HY, et al. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience 2008; 154(2): 541-50.
26. Bleau AM, Huse JT, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009; 8(18): 2936-44.
27. Kolenda J, Jensen SS, Aaberg-Jessen C, et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 2011; 103(1): 43-58.
28. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol 2002; 3(7): 397-406.
29. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28(30): 4601-8.
30. Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006; 66(4): 587-9.
31. Chang SM, Butowski NA, Sneed PK, et al. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus 2006; 20(4): E4.
32. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006; 580(12): 2903-9.
33. Quezada C, Garrido W, Oyarzun C, et al. 5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J Cell Physiol 2013; 228(3): 602-8.
34. Quezada C, Garrido W, Rocha JD, et al. Study of the role of extracellular adenosine on chemoresistance in glioblastoma stemlike cells. FEBS J 2013; 280: 201SI.
35. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005; 5(3): 198-206.
36. Zhong J, Paul A, Kellie SJ, et al. Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol 2010; 2010: 430142.
37. Díaz V, Yañez A, Ponce C, et al. Tendencia de la mortalidad por tumores cerebrales malignos en Chile. Análisis de tasas. Rev Chil Neuro-Psiquiat 2006; 44: 263-70.
38. Valera ET, de Freitas Cortez MA, de Paula Queiroz RG, et al. Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. Childs Nerv Syst 2009; 25(1): 39-45.
39. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
40. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.
41. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61(3): 215-25.
42. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 2002; 200(6): 639-46.
43. Lee SW, Kim WJ, Park JA, et al. Blood-brain barrier interfaces and brain tumors. Arch Pharm Res 2006; 29(4): 265-75.
44. Chang JE, Khuntia D, Robins HI, et al. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007; 5(11): 894-902, 907-815.
45. Stupp R, Gander M, Leyvraz S, et al. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001; 2(9): 552-60.
46. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9(1): 105-27.
47. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem 2008; 312(1-2): 71-80.
48. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009; 14(1): 3-9.
49. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5(4): 275-84.
50. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101(39): 14228-33.
51. Jeong HW, Cui W, Yang Y, et al. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS One 2011; 6(4): e18372.
52. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99(1): 319-25.
53. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100(25): 15178-83.
54. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64(19): 7011-21.
55. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432(7015): 396-401.
56. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66(16): 7843-8.
57. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serumcultured cell lines. Cancer Cell 2006; 9(5): 391-403.
58. Li G, Chen Z, Hu YD, et al. Autocrine factors sustain glioblastoma stem cell self-renewal. Oncol Rep 2009; 21(2): 419-24.
59. Anido J, Saez-Borderias A, Gonzalez-Junca A, et al. TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 2010; 18(6): 655-68.
60. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumourinitiating cells. Nature 2006; 444(7120): 761-5.
61. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11(1): 69-82.
62. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13(4): 1253-9.
63. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25(30): 4722-9.
64. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27(28): 4733-40.
65. Chamberlain MC, Johnston SK. Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. J Neurooncol 2011; 102(3): 427-32.
66. Lu-Emerson C, Norden AD, Drappatz J, et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol 2011; 104(1): 287-91.
67. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009; 73(15): 1200-6.
68. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009; 92(2): 149-55.
69. Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?. Curr Opin Neurol 2008; 21(6): 717-9.
70. Vauleon E, Avril T, Collet B, et al. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010; 2010. pii: 689171.
71. Zhang B, Jia H, Liu J, et al. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. J Immunol 2010; 185(12): 7199-206.
72. Hoa N, Ge L, Kuznetsov Y, et al. Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol 2010; 185(8): 4793-803.
73. Cardona AF, Balana C, Torres D, et al. Stem cells in brain tumorigenesis and their impact on therapy. Curr Stem Cell Res Ther 2011; 6(4): 339-49.
74. Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma-a target for antitumor therapy?. Crit Rev Oncol Hematol 2006; 59(3): 181-93.
75. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15(14): 4589-99.
76. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6): 401-10.
77. Rahman R, Smith S, Rahman C, et al. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 2010; 2010: 251231.
78. Eichhorn ME, Kleespies A, Angele MK, et al. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 2007; 392(3): 371-9.
79. Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol 2010; 2010: 689018.
80. Takano S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol 2012; 29(2): 73-86.
81. Xu C, Wu X, Zhu J. VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2. ScientificWorldJournal 2013; 2013: 417413.
82. Takano S, Yamashita T, Ohneda O. Molecular therapeutic targets for glioma angiogenesis. J Oncol 2010; 2010: 351908.
83. Piao Y, Liang J, Holmes L, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 2012; 14(11): 1379-92.
84. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468(7325): 824-8.
85. Zhao Y, Dong J, Huang Q, et al. Endothelial cell transdifferentiation of human glioma stem progenitor cells in vitro. Brain Res Bull 2010; 82(5-6): 308-12.
86. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468(7325): 829-33.
87. Yang L, Lin C, Wang L, et al. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res 2012; 318(19): 2417-26.
88. Heddleston JM, Li Z, McLendon RE, et al. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8(20): 3274-84.
89. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009; 92(3): 317-35.
90. McCord AM, Jamal M, Williams ES, et al. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009; 15(16): 5145-53.
91. Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28(45): 3949-59.
92. Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102(5): 789-95.
93. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15(6): 501-13.
94. Govaert KM, Emmink BL, Nijkamp MW, et al. Hypoxia After Liver Surgery Imposes an Aggressive Cancer Stem Cell Phenotype on Residual Tumor Cells. Ann Surg 2014; 259(4): 750-9.
95. Salnikov AV, Liu L, Platen M, et al. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One 2012; 7(9): e46391.
96. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49(3): 333-43.
97. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26(25): 4189-99.
98. Beier D, Rohrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008; 68(14): 5706-15.
99. Clement V, Sanchez P, de Tribolet N, et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell selfrenewal, and tumorigenicity. Curr Biol 2007; 17(2): 165-72.
100. Macingova Z, Filip S. Cancer stem cells-new approach to cancerogenensis and treatment. Acta Medica (Hradec Kralove) 2008; 51(3): 139-44.
101. Sullivan JP, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 2010; 29(1): 61-72.
102. Perez Castillo A, Aguilar-Morante D, Morales-Garcia JA, et al. Cancer stem cells and brain tumors. Clin Transl Oncol 2008; 10(5): 262-7.
103. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-6.
104. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5(11): 610-20.
105. Das B, Tsuchida R, Malkin D, et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008; 26(7): 1818-30.
106. Chen L, Feng P, Li S, et al. Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochem Res 2009; 34(5): 984-90.
107. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997; 57(13): 2602-5.
108. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010; 29(39): 5346-58.
109. Merighi S, Benini A, Mirandola P, et al. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 2007; 72(1): 162-72.
110. Merighi S, Benini A, Mirandola P, et al. Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. Biochem Pharmacol 2006; 72(1): 19-31.
111. Gessi S, Merighi S, Sacchetto V, et al. Adenosine receptors and cancer. Biochim Biophys Acta 2011; 1808(5): 1400-12.
112. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42(7): 1007-17.
113. Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58(7): 931-59.
114. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10(2): 159-65.
115. Hennessy M, Spiers JP. A primer on the mechanics of Pglycoprotein the multidrug transporter. Pharmacol Res 2007; 55(1): 1-15.
116. Vaalburg W, Hendrikse NH, Elsinga PH, et al. P-glycoprotein activity and biological response. Toxicol Appl Pharmacol 2005; 207(2 Suppl): 257-60.
117. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005; 65(24): 11419-28.
118. Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005; 74(2): 113-21.
119. Benyahia B, Huguet S, Decleves X, et al. Multidrug resistanceassociated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol 2004; 66(1-2): 65-70.
120. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999; 1461(2): 359-376.
121. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54(22): 5902-5910.
122. Kruh GD, Zeng H, Rea PA, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001; 33(6): 493-501.
123. Zelcer N, Saeki T, Reid G, et al. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001; 276(49): 46400-07.
124. Lai L, Tan T. M. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J 2002; 361(Pt 3): 497-503.
125. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275(39): 30069-74.
126. Aronica E, Gorter JA, Redeker S, et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005; 46(6): 849-57.
127. Xu J, Peng H, Zhang JT. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem 2007; 14(6): 689-701.
128. Awasthi S, Singhal SS, Singhal J, et al. Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. Int J Oncol 2003; 22(4): 721-32.
129. Steiner E, Holzmann K, Elbling L, et al. Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets 2006; 7(8): 923-34.
130. O'Connor R, O'Leary M, Ballot J, et al. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol 2007; 59(1): 79-87.
131. Robey RW, Shukla S, Finley EM, et al. Inhibition of Pglycoprotein (ABCB1)-and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 2008; 75(6): 1302-12.
132. Peck RA, Hewett J, Harding MW, et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001; 19(12): 3130-41.
133. de Faria GP, de Oliveira JA, de Oliveira JG, et al. Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high-grade gliomas. Cancer Invest 2008; 26(9): 883-9.
134. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7(9): 1028-34.
135. Zhou S, Zong Y, Lu T, et al. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. Biotechniques 2003; 35(6): 1248-52.
136. Piccirillo SG, Vescovi AL. Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 2006; 5: 59-81.
137. Wan F, Zhang S, Xie R, et al. The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research. Brain Pathol 2010; 20(5): 877-89.
138. Li WQ, Li YM, Tao BB, et al. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 2010; 16(10): HY27-30.
139. Jin Y, Bin ZQ, Qiang H, et al. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 2009; 135(10): 1369-76.
140. Caldera V, Mellai M, Annovazzi L, et al. MGMT hypermethylation and MDR system in glioblastoma cancer stem cells. Cancer Genomics Proteomics 2012; 9(4): 171-8.
141. Warrier S, Pavanram P, Raina D, et al. Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays. Cell Biol Int 2012; 36(12): 1137-43.
142. Nakai E, Park K, Yawata T, et al. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 2009; 27(9): 901-8.
143. Broadley KW, Hunn MK, Farrand KJ, et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011; 29(3): 452-61.
144. Linden J. Adenosine metabolism and cancer. Focus on "Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway". Am J Physiol Cell Physiol 2006; 291(3): C405-406.
145. Rathbone MP, Middlemiss PJ, Gysbers JW, et al. Trophic effects of purines in neurons and glial cells. Prog Neurobiol 1999; 59(6): 663-90.
146. Picher M, Burch LH, Hirsh AJ, et al. Ecto 5'-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 2003; 278(15): 13468-79.
147. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res 2010; 70(16): 6407-11.
148. Grobben B, Anciaux K, Roymans D, et al. An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. J Neurochem 1999; 72(2): 826-34.
149. Bavaresco L, Bernardi A, Braganhol E, et al. The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem 2008; 319(1-2): 61-8.
150. Ludwig HC, Rausch S, Schallock K, et al. Expression of CD73 (ecto-5'-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry. Anticancer Res 1999; 19(3A): 1747-52.
151. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010; 107(4): 1547-52.
152. Zhi X, Wang Y, Zhou X, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci 2010; 101(12): 2561-9.
153. Wang L, Zhou X, Zhou T, et al. Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2008; 134(3): 365-72.
154. Zhou X, Zhi X, Zhou P, et al. Effects of ecto-5'-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 2007; 17(6): 1341-6.
155. Allard B, Turcotte M, Spring K, et al. Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer 2014; 134(6): 1466-73.
156. Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011; 71(8): 2892-900.
157. Ujhazy P, Berleth ES, Pietkiewicz JM, et al. Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer 1996; 68(4): 493-500.
158. Fredholm BB, AP IJ, Jacobson KA, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53(4): 527-52.
159. San Martin R, Sobrevia L. Gestational diabetes and the adenosine/L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta 2006; 27(1): 1-10.
160. Synowitz M, Glass R, Farber K, et al. A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res 2006; 66(17): 8550-7.
161. Gessi S, Merighi S, Varani K, et al. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008; 117(1): 123-40.
162. Morrone FB, Jacques-Silva MC, Horn AP, et al. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J Neurooncol 2003; 64(3): 211-8.
163. Taliani S, Pugliesi I, Bellandi M, et al. A3 receptor ligands: past, present and future trends. Curr Top Med Chem 2010; 10(10): 942-75.
164. Gessi S, Sacchetto V, Fogli E, et al. Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol 2010; 79(10): 1483-95.
165. Merighi S, Benini A, Mirandola P, et al. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 2005; 7(10): 894-903.
166. Merighi S, Benini A, Mirandola P, et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 2007; 72(2): 395-406.
167. Liu TZ, Wang X, Bai YF, et al. The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A2B adenosine receptor. Int J Biochem Cell Biol 2014; 49: 8-16.
168. Zylka MJ, Sowa NA, Taylor-Blake B, et al. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008; 60(1): 111-22.
169. Lotsch D, Steiner E, Holzmann K, et al. Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis. Oncotarget 2013; 4(11): 1904-18.
170. Kuan CT, Wakiya K, Herndon JE, et al. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 2010; 10: 468.
171. Kang YH, Lee E, Youk HJ, et al. Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells. Cancer Lett 2005; 217(2): 181-90.
172. Decleves X, Fajac A, Lehmann-Che J, et al. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 2002; 98(2): 173-80.
173. Xu S, Shao QQ, Sun JT, et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol 2013; 15(9): 1160-72.
174. Cappellari AR, Vasques GJ, Bavaresco L, et al. Involvement of ecto-5'-nucleotidase/CD73 in U138MG glioma cell adhesion. Mol Cell Biochem 2012; 359(1-2): 315-22.